Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies — Stella

Recruiting

Back to Neuromyelitis Optica Spectrum Disorder trials

Trial locations(33 sites)

United States

Clinical Trial Site, Washington D.C., District of Columbia

Research Site, Boston, Massachusetts

Clinical Trial Site, Chapel Hill, North Carolina

Clinical Trial Site, Columbus, Ohio

Clinical Trial Site, Plano, Texas

Key details

Sponsor

Alexion Pharmaceuticals, Inc.

Enrollment target

~122 participants

Started

February 2024

Primary completion

March 2030

Age range

18 Years and older

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov